GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Divi's Laboratories Ltd (NSE:DIVISLAB) » Definitions » EV-to-EBITDA

Divi's Laboratories (NSE:DIVISLAB) EV-to-EBITDA : 45.04 (As of Apr. 28, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Divi's Laboratories EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Divi's Laboratories's enterprise value is ₹1,030,105 Mil. Divi's Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹22,871 Mil. Therefore, Divi's Laboratories's EV-to-EBITDA for today is 45.04.

The historical rank and industry rank for Divi's Laboratories's EV-to-EBITDA or its related term are showing as below:

NSE:DIVISLAB' s EV-to-EBITDA Range Over the Past 10 Years
Min: 19.3   Med: 31.96   Max: 91.91
Current: 45.04

During the past 13 years, the highest EV-to-EBITDA of Divi's Laboratories was 91.91. The lowest was 19.30. And the median was 31.96.

NSE:DIVISLAB's EV-to-EBITDA is ranked worse than
90.54% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.19 vs NSE:DIVISLAB: 45.04

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-28), Divi's Laboratories's stock price is ₹4016.35. Divi's Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹52.110. Therefore, Divi's Laboratories's PE Ratio for today is 77.07.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Divi's Laboratories EV-to-EBITDA Historical Data

The historical data trend for Divi's Laboratories's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Divi's Laboratories EV-to-EBITDA Chart

Divi's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.67 25.76 32.20 28.56 26.11

Divi's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.33 26.11 40.29 43.30 45.31

Competitive Comparison of Divi's Laboratories's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Divi's Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Divi's Laboratories's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Divi's Laboratories's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Divi's Laboratories's EV-to-EBITDA falls into.



Divi's Laboratories EV-to-EBITDA Calculation

Divi's Laboratories's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1030104.731/22871.4
=45.04

Divi's Laboratories's current Enterprise Value is ₹1,030,105 Mil.
Divi's Laboratories's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹22,871 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Divi's Laboratories  (NSE:DIVISLAB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Divi's Laboratories's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4016.35/52.110
=77.07

Divi's Laboratories's share price for today is ₹4016.35.
Divi's Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹52.110.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Divi's Laboratories EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Divi's Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Divi's Laboratories (NSE:DIVISLAB) Business Description

Traded in Other Exchanges
Address
Divi Towers, 1-72/23(P)/DIVIS/303, Babukhan Lane, Cyber Hills, Gachibowli, Hyderabad, TG, IND, 500032
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. The company has three distinct business segments: Generic APIs, Custom Synthesis, and Nutraceuticals. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Divi's Laboratories (NSE:DIVISLAB) Headlines

No Headlines